Bioventus INC Form 4 insider transactions

Bioventus Inc. Director Susan M. Stalneckner reported the vesting of 26,493 restricted stock units into Class A common stock and the grant of an additional 32,282 restricted stock units.

Bioventus Inc. Director Guy P. Nohra reported the vesting of 26,493 restricted stock units into Class A Common Stock and the acquisition of 32,282 new restricted stock units.

Bioventus Inc. Director Guido J. Neels acquired 26,493 shares of Class A Common Stock through the vesting of restricted stock units and was granted an additional 32,282 restricted stock units.

Bioventus Inc. Director Michelle McMurry-Heath reported the acquisition of 26,493 Class A Common Stock shares through RSU vesting and received a new grant of 32,282 Restricted Stock Units.

Bioventus Inc. Director Mary Kay Ladone reported the acquisition of 26,493 Class A Common Stock shares through RSU vesting and a new grant of 32,282 Restricted Stock Units.

Bioventus Inc. Director William A. Hawkins reported the vesting of 26,493 restricted stock units into common stock and the grant of 39,789 new restricted stock units, increasing his total beneficial ownership.

Bioventus Inc. Director Philip G. Cowdy has reported the acquisition of 32,282 Restricted Stock Units (RSUs) and beneficial ownership of 11,700 Class A Common Stock shares, as detailed in a recent SEC Form 4 filing.

Bioventus Inc. Director Pat Beyer reported the vesting of 26,493 restricted stock units into Class A common stock and the acquisition of 32,282 new restricted stock units.

Mark Leonard Singleton, SVP & CFO of Bioventus Inc., reports the sale of 3,875 shares of Class A Common Stock to cover taxes upon the vesting of restricted stock units.

Anthony D'Adamio, SVP & General Counsel of Bioventus Inc., sold 2,958 shares of Class A Common Stock on April 11, 2025, to cover taxes upon the vesting of restricted stock units.

Katrina J. Church, SVP & Chief Compliance Officer of Bioventus Inc., reports selling 1,283 shares of Class A Common Stock to cover taxes upon vesting of restricted stock units.

Mark Leonard Singleton, SVP & CFO of Bioventus Inc., reports the vesting of restricted stock units and subsequent acquisition of Class A Common Stock on April 10, 2025.

Anthony D'Adamio, SVP & General Counsel of Bioventus Inc., exercised stock options to acquire 9,925 shares of Class A Common Stock on April 10, 2025.

Katrina J. Church, SVP & Chief Compliance Officer of Bioventus Inc., exercised stock options and acquired 4,300 shares of Class A Common Stock on April 10, 2025.

Mark Leonard Singleton, SVP & CFO of Bioventus Inc., reports the sale of 5,479 shares of Class A Common Stock to cover taxes upon vesting of restricted stock units.

Mark Leonard Singleton, SVP & CFO of Bioventus Inc., reports the vesting of restricted stock units and subsequent acquisition of Class A Common Stock on March 21, 2025.

Katrina J. Church, SVP & Chief Compliance Officer of Bioventus Inc., sold 1,018 shares of Class A Common Stock to cover taxes upon the vesting of restricted stock units.

Anthony D'Adamio, SVP & General Counsel of Bioventus Inc., sold 2,615 shares of Class A Common Stock to cover taxes upon the vesting of restricted stock units.

Katrina J. Church, SVP & Chief Compliance Officer of Bioventus Inc., reports the acquisition of 3,456 shares of Class A Common Stock through the exercise of restricted stock units on March 14, 2025.

Anthony D'Adamio, SVP & General Counsel of Bioventus Inc., reports the vesting and conversion of restricted stock units into Class A Common Stock.

Mark Leonard Singleton, SVP & CFO of Bioventus Inc., sold 6,498 shares of Class A Common Stock to cover taxes upon the vesting of restricted stock units.

Anthony D'Adamio, SVP & General Counsel of Bioventus Inc., sold 4,380 shares of Class A Common Stock to cover taxes upon the vesting of restricted stock units.

Katrina J. Church, SVP & Chief Compliance Officer of Bioventus Inc., sold 1,537 shares of Class A Common Stock to cover taxes upon the vesting of restricted stock units.

Mark Leonard Singleton, SVP & CFO of Bioventus Inc., reports the disposition of 20,153 shares of Class A Common Stock to satisfy vesting requirements of restricted stock units.

Anthony D'Adamio, SVP & General Counsel of Bioventus Inc., reports exercising stock options resulting in the acquisition of 12,980 shares of Class A Common Stock.

Katrina J. Church, SVP & Chief Compliance Officer of Bioventus Inc., reports the vesting of restricted stock units and subsequent acquisition of Class A Common Stock on February 15, 2025.

Bioventus Inc.'s CEO, Robert E. Claypoole, sold 28,786 shares of Class A Common Stock to cover taxes following the vesting of restricted stock units.

Robert E. Claypoole, President and CEO of Bioventus Inc., reports the vesting and conversion of restricted stock units into Class A Common Stock on January 10, 2025.

Bioventus Inc.'s SVP & CFO, Mark Leonard Singleton, sold 10,733 shares of Class A Common Stock to cover taxes after restricted stock units vested.

Katrina J. Church, SVP & Chief Compliance Officer at Bioventus Inc., sold 2,535 shares of Class A Common Stock to cover taxes after restricted stock units vested.